Overview

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

Status:
COMPLETED
Trial end date:
2025-06-10
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.
Phase:
PHASE1
Details
Lead Sponsor:
Incyte Corporation
Treatments:
axatilimab